BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation

American Journal of Surgical Pathology

Volumn 39, Issue 4, 2015, Pages 528-540

  Kleinschmidt DeMasters, Bette K ^a   Aisner, Dara L ^a   Foreman, Nicholas K ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

anaplastic pleomorphic xanthoastrocytoma; BRAF; epithelioid glioblastoma; Sanger sequencing; targeted therapy; vemurafenib

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; TUMOR MARKER; VEMURAFENIB;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CHILD; ENZYMOLOGY; EPITHELIOID CELL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC PREDISPOSITION; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; DNA MUTATIONAL ANALYSIS; EPITHELIOID CELLS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INDIVIDUALIZED MEDICINE; INDOLES; MALE; MIDDLE AGED; MUTATION; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84925963434     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000363     Document Type: Conference Paper

References (29)

1. Rosenblum MK, Erlandson RA, Budzilovich GN. The lipid-rich epithelioid glioblastoma. Am J Surg Pathol. 1991;15:925-934
2. Fuller GN, Goodman JC, Vogel H, et al. Epithelioid glioblastoma: a distinct clinicopathologic entity. J Neuropathol Exp Neurol. 1998;57:501
3. Akimoto J, Namatame H, Haraoka J, et al. Epithelioid glioblastoma: a case report. Brain Tumor Pathol. 2006;22:21-27
4. Rodriguez FJ, Scheithauer BW, Giannini C, et al. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer. 2008;113:2779-2789
5. Gasco J, Franklin B, Fuller GN, et al. Multifocal epithelioid glioblastoma mimicking cerebral metastasis: case report. Neurocirugia (Astur). 2009;20:550-554
6. Tanaka S, Nakada M, Hayashi Y, et al. Epithelioid glioblastoma changed to typical glioblastoma: the methylation status of MGMT promoter and 5-ALA fluorescence. Brain Tumor Pathol. 2011;28: 59-64
7. Giannini C, Scheithauer BW, Burger PC, et al. Pleomorphic xanthoastrocytoma. Cancer. 1999;85:2033-2045
8. Schmidt Y, Kleinschmidt-DeMasters BK, Aisner DL, et al. Anaplastic PXA in adults: case series with clinicopathologic and molecular features. J Neurooncol. 2013;111:59-69
9. Kleinschmidt-DeMasters BK, Alassiri AH, Birks DK, et al. Epithelioid versus rhabdoid glioblastomas are distinguished by monosomy 22 and immunohistochemical expression of INI-1 but not claudin 6. Am J Surg Pathol. 2010;34:341-354
10. Kleihues P, Burger PC, Aldape KD, et al. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Albany, New York: WHO Publications Center; 2007:33-49
11. Kleinschmidt-De Masters BK, Aisner DL, Birks DK, et al. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013;37:658-698
12. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397-405
13. Chapman PB, Hauschild A, Robert C, et al. Improved Survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516
14. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714
15. Donson AM, Kleinschmidt-DeMasters BK, Aisner DL, et al. Pediatric brainstem gangliogliomas show BRAF V600E mutation in a high percentage of cases. Brain Pathol. 2014;24:173-183
16. Lummus SC, Aisner DL, Sams SB, et al. Massive dissemination from spinal cord gangliogliomas negative for BRAF V600E: report of two rare adult cases. Am J Clin Pathol. 2014;142: 254-260
17. Nobusawa S, Hirato J, Kurihara H, et al. Intratumoral heterogeneity of genomic imbalance in a case of epithelioid glioblastoma with BRAF V600E mutation. Brain Pathol. 2014;24:239-246
18. Koelsche C, Wohrer A, Jeibmann A, et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol. 2013;125:891-900
19. Sperveslage J, Gierke M, Capper E, et al. VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation. Acta Neuropathol. 2013;125:911-912
20. Mordes DA, Lynch K, Campbell S, et al. VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations. Am J Clin Pathol. 2014;141:811-815
21. Farzin M, Toon CW, Clarkson A, et al. BRAF V600E mutation specific immunohistochemistry with clone VE1 is not reliable in pituitary adenomas. Pathology. 2014;46:79-80
22. Kuan S-F, Navina S, Cressman KL, et al. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization. Hum Pathol. 2014;45: 464-472
23. Chen LI, Voronovich Z, Clark K, et al. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnosis of infiltrative glioma. Neuro Oncol. 2014;16:1478-1483
24. Bautista F, Paci A, Minard-Colin V, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61:1101-1103
25. Rush S, Foreman N, Liu A. Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol. 2013;31: e159-e160
26. Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 2014;14:258
27. Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol. 2013;114:237-240
28. Lee EQ, Ruland S, LeBoeuf NR, et al. Successful treatment of a progressive BRAF V600E-mutated anaplastic pleomorphic xanthoastrocytoma with vemurafenib monotherapy. J Clin Oncol. 2014. [Epub ahead of print
29. Skrypek M, Foreman N, Guillaume D, et al. Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr Blood Cancer. 2014;61:2099-2100